At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRAL GRAIL, Inc.
Trading 10-15 13:53:10 EDT
137.88
-1.82
-1.30%
High139.50Low132.09Vol377.19K
Open136.00D1 Closing139.70Amplitude5.30%
Mkt Cap6.16BTradable Cap5.62BTotal Shares44.67M
T/O51.39MT/O Rate0.93%Tradable Shares40.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Grail Price Target Raised to $120.00/Share from $60.00 by Morgan Stanley
Dow Jones  ·  10-14 00:39
Grail Price Target Raised to $120.00/Share from $60.00 by Morgan Stanley
Grail Rises as TD Cowen More than Doubles PT on FDA, Medicare Optimism
Reuters  ·  10-14 00:09
Grail Rises as TD Cowen More than Doubles PT on FDA, Medicare Optimism
Morgan Stanley Sticks to Their Hold Rating for GRAIL Inc (GRAL)
TIPRANKS  ·  10-13 20:56
Morgan Stanley Sticks to Their Hold Rating for GRAIL Inc (GRAL)
Analyst Reinstates Coverage With Hold Rating as Packaging Recovery Offsets High Leverage and Machinery Weakness
TIPRANKS  ·  10-12
Analyst Reinstates Coverage With Hold Rating as Packaging Recovery Offsets High Leverage and Machinery Weakness
Galleri Trial Data Might Change The Case For GRAIL Stock
Simply Wall St.  ·  10-11
Galleri Trial Data Might Change The Case For GRAIL Stock
Movement Alert｜GRAIL, Inc. Rises 5.56% in Regular Trading, FDA Advisory Committee Favorable Vote Continues to Catalyze
Market Focus  ·  10-09
Movement Alert｜GRAIL, Inc. Rises 5.56% in Regular Trading, FDA Advisory Committee Favorable Vote Continues to Catalyze
Movement Alert｜GRAIL, Inc. Rises 5.14% in Regular Trading, FDA Panel's Positive Vote on Galleri Continues to Drive Momentum
Market Focus  ·  10-06
Movement Alert｜GRAIL, Inc. Rises 5.14% in Regular Trading, FDA Panel's Positive Vote on Galleri Continues to Drive Momentum
Movement Alert｜GRAIL, Inc. Rises 6.76% in Pre-Market Trading, FDA Advisory Committee Favorable Vote on Galleri Continues to Catalyze
Market Focus  ·  10-06
Movement Alert｜GRAIL, Inc. Rises 6.76% in Pre-Market Trading, FDA Advisory Committee Favorable Vote on Galleri Continues to Catalyze
Grail to Present New NHS-Galleri, Pathfinder 2 Data on Galleri Cancer Test at EDCC, ESMO 2026
Reuters  ·  10-06
Grail to Present New NHS-Galleri, Pathfinder 2 Data on Galleri Cancer Test at EDCC, ESMO 2026
Movement Alert｜GRAIL, Inc. Intraday Rise 5.13%, UBS Price Target Hike to $175 Spurs Investor Confidence
Market Focus  ·  10-05
Movement Alert｜GRAIL, Inc. Intraday Rise 5.13%, UBS Price Target Hike to $175 Spurs Investor Confidence
UBS Adjusts GRAIL Price Target to $175 From $105, Maintains Buy Rating
MT Newswires Live  ·  10-02
UBS Adjusts GRAIL Price Target to $175 From $105, Maintains Buy Rating
Movement Alert｜GRAIL, Inc. Rises 6% in Regular Trading, FDA Advisory Committee Favorable Vote Continues to Drive Stock Rebound
Market Focus  ·  10-02
Movement Alert｜GRAIL, Inc. Rises 6% in Regular Trading, FDA Advisory Committee Favorable Vote Continues to Drive Stock Rebound
Grail Inc : UBS Raises Target Price to $175 from $105
THOMSON REUTERS  ·  10-02
Grail Inc : UBS Raises Target Price to $175 from $105
Grail's Cancer Blood Test Nears Landmark FDA Approval, but Insurance Coverage Looms
Reuters  ·  10-02
Grail's Cancer Blood Test Nears Landmark FDA Approval, but Insurance Coverage Looms
Movement Alert｜GRAIL, Inc. Falls 5.07% in Regular Trading, Post-FDA Advisory Committee Rally Triggers Profit-Taking
Market Focus  ·  10-02
Movement Alert｜GRAIL, Inc. Falls 5.07% in Regular Trading, Post-FDA Advisory Committee Rally Triggers Profit-Taking
Grail price target raised to $155 from $75 at Guggenheim
TIPRANKS  ·  10-01
Grail price target raised to $155 from $75 at Guggenheim
A Cancer Test Has Investors Betting Big. but Will Insurers Pay? - Heard on the Street
Dow Jones  ·  10-01
A Cancer Test Has Investors Betting Big. but Will Insurers Pay? - Heard on the Street
Movement Alert｜GRAIL, Inc. Rises 5.27% in Regular Trading, FDA Advisory Committee Unanimously Approves Galleri Safety and Supports Approval
Market Focus  ·  09-30
Movement Alert｜GRAIL, Inc. Rises 5.27% in Regular Trading, FDA Advisory Committee Unanimously Approves Galleri Safety and Supports Approval
Movement Alert｜GRAIL, Inc. Rises 5.69% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Multi-Cancer Detection Test
Market Focus  ·  09-28
Movement Alert｜GRAIL, Inc. Rises 5.69% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Multi-Cancer Detection Test
Grail is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  09-28
Grail is Maintained at Buy by Canaccord Genuity
No data available

Introduction

Company Name.
GRAIL, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Grail, Inc. was incorporated in Delaware on September 11, 2015. The company is a healthcare company dedicated to saving lives and improving health by pioneering new technologies for early cancer detection. It has built a multidisciplinary organization of scientists, engineers, and physicians, leveraging the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer and data science to overcome one of medicine's greatest challenges. Using its platform technology, the company has developed a multi-cancer early detection blood test that has demonstrated in clinical studies the ability to detect over 50 cancer types from a single blood draw while accurately identifying the origin of the cancer signal with high precision.
Issue price:
--